On-Q-ity

NEW YORK (GenomeWeb News) – Circulating tumor cell test development firm On-Q-ity has closed its doors, according to a venture capital investor in the firm.

On-Q-ity, a company developing diagnostics that analyze circulating tumor cells to guide treatment strategies for various cancers, announced that its board of directors has appointed Michael Stocum as president and CEO.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – On-Q-ity today announced it has raised $5 million in financing and it has appointed Michael Stocum as the company's president and CEO.

The microfluidic chip, called the On-Q-ity Circulating Cancer Capture and Characterization Chip, or C5, uses both antibody affinity and size to filter CTCs from normal blood. In a study comparing C5 and a chip using antibody affinity alone, On-Q-ity's dual capture chip "greatly improved" capture rate over the comparator.

In an interview with GenomeWeb Daily News, On-Q-ity CEO Mara Aspinall touted the advantages of the firm's platform and discussed its potential to monitor patients in clinical trials at a level not currently possible.

LabCorp will market the platform to biopharma researchers conducting clinical studies of oncology drugs.

Pairings

Premium

Patrick Terry, Walter Carney

The startup has now raised a total of $26 million in Series A financing to support development of a biomarker-based cancer diagnostic.

On-Q-ity is developing a cancer diagnostic platform that combines monitoring DNA repair biomarkers to predict treatment response and microfluidic chips that enable the capture, enumeration, and characterization of circulating tumor cells in a patient's bloodstream.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.